Who Supplies Paracetamol to India from POLAND

To import finished pharmaceutical formulations containing Paracetamol into India, the foreign manufacturer must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The Central Drugs Standard Control Organisation (CDSCO) requires registration of the product, which involves submitting Form 40 or 41, depending on the product type. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for import drug registration varies but typically ranges from 6 to 12 months. Paracetamol formulations under HS Code 30049069 are subject to these requirements.

Imported Paracetamol formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is mandatory, and a Certificate of Analysis (CoA) is required for each batch. Stability data must comply with International Council for Harmonisation (ICH) guidelines, specifically for Zone IV conditions. The Indian Pharmacopoeia standards must be met. Upon arrival, customs drug inspectors conduct port inspections to verify compliance.

As of April 2020, the Indian government permitted the export of Paracetamol formulations, including Fixed Dose Combinations (FDCs), under any ITC HS Code, making them "Free" for export. However, Paracetamol Active Pharmaceutical Ingredients (APIs) remain restricted for export. This policy change aims to balance domestic supply with international demand.

India imports finished Paracetamol formulations to meet domestic demand for patented or branded products, specific dosage forms, and formulations not produced locally. The market size for Paracetamol formulations in India is substantial, with a total export market of $357.3 million across 870 exporters to 170 countries. This indicates a significant domestic consumption and reliance on imports to fulfill certain market segments.

The Basic Customs Duty (BCD) for Paracetamol formulations under HS Code 30049069 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is levied. The total landed duty amounts to approximately 23.536%, calculated as follows:

• Assessable Value (A) = CIF Value + 1% Landing Charge of CIF
• Basic Duty (B) = A × 10%
• IGST (C) = (A + B) × 12%
• SWS (F) = (A + B + C) × 10%
• Total Duty = B + C + F

This structure ensures that imported Paracetamol formulations are subject to a comprehensive duty framework upon entry into India.

India sources Paracetamol formulations from Poland due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Poland's pharmaceutical industry is known for its adherence to European Union (EU) GMP standards, which are recognized by Indian authorities. While other suppliers like China, Germany, and the United States also export Paracetamol formulations to India, Poland's competitive advantage lies in its quality compliance and the ability to supply specific formulations not readily available from other sources.

India imports Paracetamol formulations from Poland due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Poland's pharmaceutical industry adheres to EU GMP standards, which are recognized by Indian authorities, ensuring product quality and safety. Additionally, Poland can supply specific formulations not readily available from other sources, meeting unique market demands in India.

Compared to other sources like China, Germany, and the United States, Poland offers competitive advantages in terms of quality compliance and the ability to supply specific formulations. While China may offer lower prices, concerns about quality and regulatory compliance can be a deterrent. Germany and the United States provide high-quality products but may have higher costs. Poland's unique advantage lies in its balance of quality, compliance, and cost-effectiveness.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with suppliers. Monitoring regulatory changes and having contingency plans for shipping disruptions are also crucial.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letter of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order sizes with market demand to optimize inventory.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with regulatory standards.

1. 1DGFT Import License: Obtain a valid license from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with the Central Drugs Standard Control Organisation.
3. 3Form 40/41: Submit the appropriate form based on the product type.